MedPath

Evommune, Inc.

Evommune, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2020-01-01
Employees
11
Market Cap
-
Website
http://www.evommune.com

Clinical Trials

4

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (100.0%)

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Phase 2
Recruiting
Conditions
Chronic Spontaneous Urticaria
Interventions
Drug: Placebo control
First Posted Date
2025-03-12
Last Posted Date
2025-07-17
Lead Sponsor
Evommune, Inc.
Target Recruit Count
160
Registration Number
NCT06873516
Locations
🇺🇸

Cahaba Dermatology Skin Health Center, Birmingham, Alabama, United States

🇺🇸

Velocity Clinical Research, Mobile, Mobile, Alabama, United States

🇺🇸

Center for Dermatology Clinical Research, Fremont, California, United States

and more 38 locations

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Phase 2
Recruiting
Conditions
Atopic Dermatitis (AD)
Eczema
Eczema Atopic Dermatitis
Interventions
Biological: Placebo
First Posted Date
2024-12-09
Last Posted Date
2025-03-18
Lead Sponsor
Evommune, Inc.
Target Recruit Count
60
Registration Number
NCT06723405
Locations
🇦🇺

Cornerstone Dermatology, Coorparoo, Australia

🇦🇺

Momentum Clinical Research Darlinghurst, Darlinghurst, Australia

🇳🇿

Pacific Clinical Research Network (PCRN) Auckland, Auckland, New Zealand

and more 9 locations

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Phase 2
Completed
Conditions
Chronic Inducible Urticaria
Interventions
Drug: Oral EVO756
First Posted Date
2024-09-19
Last Posted Date
2025-06-18
Lead Sponsor
Evommune, Inc.
Target Recruit Count
30
Registration Number
NCT06603220
Locations
🇺🇸

Cahaba Dermatology & Skin Health Center, LLC, Birmingham, Alabama, United States

🇺🇸

California Allergy and Asthma Medical Group, Los Angeles, California, United States

🇺🇸

Integrative Skin Science and Research, Sacramento, California, United States

and more 15 locations

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis Eczema
Interventions
First Posted Date
2022-10-14
Last Posted Date
2025-03-05
Lead Sponsor
Evommune, Inc.
Target Recruit Count
119
Registration Number
NCT05579899
Locations
🇺🇸

Saguaro Dermatology, Phoenix, Arizona, United States

🇺🇸

Clinical Trials Institute of Northwest Arkansas, Fayetteville, Arkansas, United States

🇺🇸

Northwest AR Clinical Trials Center, PLLC, Rogers, Arkansas, United States

and more 18 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.